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Objectives
●
●
●
●
●
●

Deﬁne PCOS
Outline varying diagnostic criteria
Brieﬂy review pathophysiology and diagnostic approach
Review primary care management of PCOS symptoms
Summarize role of PCP for clinical monitoring
Explore inﬂuence of PCOS on fertility and pregnancy

I won’t be covering:
Advanced infertility treatment
Management of Diabetes
Management of complications of
pregnancy

Advanced workup for endocrine
disorder such as Cushings, CAH,
Acromegaly
Psychological Impact of PCOS

Our Patient
CM is a 26 yo patient (she/her) with no signiﬁcant PMH coming in for a
routine gyn visit. She is due for her pap and she reports irregular periods
occurring every 1-3 months. She also notes that she has noticed a lot more
facial hair develop along her chin over the past year which is really
bothering her.
VSS.
Physical exam remarkable for BMI 33, mild acne along jawline, and notable
facial hair on upper lip, outer cheeks, jawline and upper neck.
Multiple striae are observed on abdomen and her chest.
GU exam is normal, anteverted uterus on bimanual exam. Pap performed.
Remainder of exam within normal limits.

Deﬁnition:
Most common endocrinopathy of reproductive-age patients with ovaries with
a constellation of symptoms including a combination of irregular menses,
hyperandrogenism, insulin resistance/hyperinsulinism, obesity, and potential
changes to ovarian morphology.

Precise etiology is unknown but thought to be a complex interplay
of genetics and environment leading to insulin resistance and
ovarian overproduction of androgens.

7-10%
Of reproductive-age people with ovaries have this condition
(approximately 5 million people in the US)
PCOS linked to multiple comorbidities!
We have many ways to treat it.

Diagnostic Schema
Signs & Symptoms

NIH Criteria (1990)

Androgen Excess
Society (2006)

Rotterdam Criteria
(2003) - 2 out of 3
required for Dx

Hyper androgenism

Required

Required

Not required

Oligomenorrhea
Amenorrhea

Required

Not required

Not required

Polycystic ovaries by
ultrasound diagnosis

Not required

Not required

Not required

Adapted from ACOG Practice Bulletin #194

NIH Criteria (1990)
Exclude other causes of hyperandrogenism and anovulation.
Oligo/Anovulation : unpredictable menses <21 days apart or >35 days apart (but
overall less than 6 months apart), 2 years after menarche
PLUS
Clinical or lab ﬁndings of hyperandrogenism

Rotterdam Criteria (2003)
Exclude other causes of hyperandrogenism and anovulation.
ANY TWO of the following:
-

Polycystic ovaries on transabd or transvaginal ultrasound
Chronic anovulation or oligovulation
Hyperandrogenism

More sensitive criteria overall!

Androgen Excess Society (2006)
Requires clinical or lab ﬁndings of hyperandrogenism
AND
Anovulation/Oligovulation or polycystic ovaries

What about adolescent patients?
Wait until at least 2 years after menarche
Recommend all three criteria for diagnosis by Endocrine Society
*Issues with ultrasound sensitivity in adolescent ovarian morphology

Thyroid disease
Prolactin disorder

Diﬀerential
Diagnosis

Congenital Adrenal Hyperplasia
(Late Onset)
Androgen-Secreting Tumors
Acromegaly
Genetic Defects in Insulin Action
Primary hypothalamic amenorrhea
Primary Ovarian Failure
PCOS!

Clinical Findings on Physical Exam
-

Elevated BMI, higher sensitivity with BMI >30
Waist circumference >35 inches
Presence of features suggestive of
hyperinsulinism or hyperandrogenism:
-

Acne
Hirsutism
Male pattern alopecia
Acanthosis Nigricans
Courtesy of MerckManuals

What initial labs would
you order for our patient?

Initial Workup (Hint: you want to exclude other causes!)
-

Pregnancy test
TSH
Prolactin
Fasting 17- OH progesterone
-

If >200 ng/dL then ACTH stim test

Other tests:
-

Hemoglobin A1c or two hour glucose
tolerance test
Lipids
Total testosterone and SHBG or
bioavailable and free testosterone
DHEAS (in rapid virilization - adrenal?)
Transvaginal Ultrasound

Ultrasound Findings

What is this ﬁnding called?

Case courtesy of Dr J. Ray Ballinger, Radiopaedia.org, rID: 23638

>8 yrs post menarche & using TVUS:
-

Ultrasound
Diagnostic
Criteria

Follicle # per ovary >20 and/or
Ovarian Volume >10cc

Transabdominal scanning - Ovarian
volume threshold >10cc
*TVUS and abd US should not be used in
adolescent females given multi-follicular
ovaries in this life stage.
Other morphology:

Radiologic Guideline

-

Peripheral location of follicles (string
of pearls)
Hyperechoic central stroma
Follicles of similar size measuring
2-9mm

Courtesy of AAFP

Are FSH & LH
useful in the
lab workup?

Symptom Management

Menstrual Irregularities
Combined OCPs, combined OCPs, combined OCPS!
-

Reduce circulating free androgens and decrease hyperandrogenism
symptoms
Decrease risk of endometrial cancer
Creates predictable monthly withdrawal bleeding during placebo

Proven to be more effective than progestin only methods including:
- Depot (medroxyprogesterone acetate)
- PO medroxyprogesterone acetate
- Progestin containing IUD
*Associated with higher incidence of irregular bleeding (~50% of patients)

Dermatological Manifestations
Acne
-

Combo OCPs
Spironolactone (50-200mg BID)
Flutamide (200mg)** - androgen receptor agonist
Antibiotics (topical or oral)
Retinoids

Alopecia
-

Combo OCPs
Spironolactone (50-200mg BID)
Flutamide (250 mg BID)**

Dermatological Manifestations
Hirsutism- prevalence of 70% of patients
-

Combo OCPS
Spironolactone 25-100mg daily
Thiazolididones (pioglitazone, rosiglitazone)
Laser therapy
Laser therapy + Elfornithine

Weak level of data on Finasteride and Flutamide

Metabolic
Obesity
- Weight Loss has the best efﬁcacy for almost all symptoms of PCOS
- Decreases circulating androgens by increasing SHBG
- Just a 5% decrease in body weight showed improvements in ovulation
Insulin Resistance
- Metformin 750-1000mg BID plus lifestyle modiﬁcations

Integrative Approaches to PCOS
-

Diet changes for weight loss
Stress reduction using exercise, meditation, acupuncture
Supplements:
- Adaptogens: Ashwaganda, holy basil, rhodiola, and maca root
- Licorice - lowering testosterone levels (avoid in HTN)
- Inositol for non-obese patients

Limited data on supplements effectiveness. Great data on exercise and weight loss
as effective method.

Wrapping up our case…
CM found to have A1c 6.0, normal lipid panel,
normal TSH, prolactin, 17-OH progest, normal
ovaries on ultrasound
- Started on metformin 500mg BID
- Combined oral contraceptive pill
- Counseled on weight loss and lifestyle
modiﬁcations

Case #2
PC is a 31 yo patient (she/her) presenting with concerns for
infertility. She and her partner have been trying to conceive
for 9 months. She has hx of PCOS, on metformin 500mg BID,
On combo OCPs (stopped 9 months ago).
BMI of 32, A1c 5.9%, Lipids with total cholesterol 220, trigly
normal.

How do you counsel her?

Two thirds
Of people with PCOS are able to conceive within one
year without any medical intervention.

Infertility and PCOS
-

Weight Loss
Metformin 500- 1000mg BID**
Ovulation Induction
Early A1c at beginning of pregnancy, early GTT (20-24
weeks)

Ovulation Induction
-

-

Clomiphene - selective estrogen receptor modulator
- 50-100mg daily for 5 days on day 3-5 of cycle
Letrozole - non steroidal competitive inhibitor of aromatase
- 2.5-7.5 daily for 5 days
- associated with higher live-birth rates and ovulation rates compared in
clomiphene
Metformin for fertility is controversial
- 2012 Cochrane study refuted this though widely used

Complications in pregnancy
● Increased risk of preterm delivery
● Increased risk of gestational diabetes
● Increased risk of hypertensive disorders of pregnancy

Role of the PCP…
We’ve touched on this a bit

Diabetes & PCOS
-

Four-fold risk of type 2 diabetes in women with PCOS

-

Metformin shown to improve glucose tolerance, decrease circulating
androgen

-

Thiazolidinediones as well but has weight gain side effect

Dyslipidemia & PCOS
-

70% of people with PCOS have dyslipidemia

-

Emerging research about role of statins in reducing cardiovascular effects of PCOS
on patients

-

Long term effects of preventing CVD in young women with PCOS is unknown

Endometrial Cancer & PCOS
-

Recommend against routine ultrasound
Management: OCPs for prevention of endometrial hyperplasia
Endometrial biopsy can be done when indicated
Rate of endometrial cancer 2.7 times as high in patients with
PCOS compared to general population

Decrease metabolic syndrome and cardiovascular
Sequelae
1.
2.
3.
4.
5.

Monitor for insulin resistance q1-3 years
Check lipids q2 years
Use metformin and statins when indicated
Counsel on fertility early
Screen for psychological eﬀects: depression,
anxiety, sleep disturbance
6. Screen for OSA
7. Later in life, screen for NAFLD

Summary
1.
2.
3.
4.
5.
6.
7.
8.

PCOS is prevalent and treatable!
Diagnosis is based on the exclusion of other causes and can be made clinically (you
don’t always need the ultrasound)
Treat the symptoms
Lifestyle modiﬁcations go a long way
Weight loss (even 5%) is the most effective treatment for every complications of
PCOS
Combined OCPs are your ﬁrst line for menstrual irregularities and derm
manifestations
Goal is to decrease the cardiovascular and metabolic sequelae of PCOS
Early fertility counseling

Questions?

Thank you!
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